Literature DB >> 28692110

Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.

Dorien Leenaerts, Jef Aernouts, Pieter Van Der Veken, Yani Sim, Anne-Marie Lambeir, Dirk Hendriks1.   

Abstract

Carboxypeptidase U (CPU, CPB2, TAFIa) is a basic carboxypeptidase that is able to attenuate fibrinolysis. The inactive precursor procarboxypeptidase U is converted to its active form by thrombin, the thrombin-thrombomodulin complex or plasmin. The aim of this study was to investigate and characterise the time course of CPU generation in healthy individuals. In plasma of 29 healthy volunteers, CPU generation was monitored during in vitro clot lysis. CPU activity was measured by means of an enzymatic assay that uses the specific substrate Bz-o-cyano-Phe-Arg. An algorithm was written to plot the CPU generation curve and calculate the parameters that define it. In all individuals, CPU generation was biphasic. Marked inter-individual differences were present and a reference range was determined. The endogenous CPU generation potential is the composite effect of multiple factors. With respect to the first CPU activity peak characteristics, we found correlations with baseline proCPU concentration, proCPU Thr325Ile polymorphism, time to clot initiation and the clot lysis time. The second CPU peak related with baseline proCPU levels and with the maximum turbidity of the clot lysis profile. In conclusion, our method offers a technique to determine the endogenous CPU generation potential of an individual. The parameters obtained by the method quantitatively describe the different mechanisms that influence CPU generation during the complex interplay between coagulation and fibrinolysis, which are in line with the threshold hypothesis.

Entities:  

Keywords:  TAFI); Thrombin activatable fibrinolysis inhibitor (proCPU; carboxypeptidase B2; carboxypeptidases; clot lysis time; fibrinolysis; proCPB2

Mesh:

Substances:

Year:  2017        PMID: 28692110     DOI: 10.1160/TH17-02-0097

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Carboxypeptidase N2 as a Novel Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma.

Authors:  Ting Xu; Zhe Zhang; Hongqiang Chen; Ruili Cai; Qian Yang; Qi Liu; Yahan Fan; Wenbin Liu; Chunyan Yao
Journal:  Front Oncol       Date:  2022-05-23       Impact factor: 5.738

2.  Liver-Dependent Lung Remodeling during Systemic Inflammation Shapes Responses to Secondary Infection.

Authors:  Christine V Odom; Yuri Kim; Claire L Burgess; Lillia A Baird; Filiz T Korkmaz; Elim Na; Anukul T Shenoy; Emad I Arafa; TuKiet T Lam; Matthew R Jones; Joseph P Mizgerd; Katrina E Traber; Lee J Quinton
Journal:  J Immunol       Date:  2021-09-01       Impact factor: 5.422

Review 3.  Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

Authors:  Karen Claesen; Joachim C Mertens; Dorien Leenaerts; Dirk Hendriks
Journal:  Int J Mol Sci       Date:  2021-01-17       Impact factor: 5.923

4.  Changes on proteomic and metabolomic profile in serum of mice induced by chronic exposure to tramadol.

Authors:  Shukun Jiang; Guojie Liu; Huiya Yuan; Enyu Xu; Wei Xia; Xiaoyu Zhang; Junting Liu; Lina Gao
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

Review 5.  Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.